ClinicalTrials.gg

Program

PI3K p110beta/delta Inhibitor CVL237

Also written as “CVL237 tablets” and “KA2237”.

Its studies are mostly in Stomach Neoplasms · Lymphoma, B-Cell, led by 2 companies.

Furthest: phase 3, since Feb 18, 20244 company-led studies, 3 open or runningNext primary completion: Jan 9, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Convalife (Shanghai)33 open or runningphase 3since Feb 18, 2024Nov 26, 2023Jan 9, 2028phase 2 · NCT07446049
Karus Therapeutics10 open or runningphase 1since Jan 29, 2016Jan 29, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 29, 2016First study: phase 1 study in Lymphoma, B-CellNew to Karus TherapeuticsKarus Therapeutics · NCT02679196 · 23 enrolled · United States
  2. Nov 26, 2023Convalife (Shanghai)’s first study: phase 2 study in Stomach NeoplasmsNew to Convalife (Shanghai)Convalife (Shanghai) · NCT06183736 · 98 planned · China
  3. Feb 18, 2024Phase 3 study in Hereditary Sensory and Autonomic NeuropathiesConvalife (Shanghai) · NCT06293716 · 35 planned · China
  4. Jun 26, 2025Phase 2 study in Stomach NeoplasmsConvalife (Shanghai) · NCT07446049 · 180 planned

Ahead

  1. Jan 9, 2028Primary completion: phase 2 study in Stomach NeoplasmsConvalife (Shanghai) · NCT07446049

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07446049Stomach Neoplasms2Not yet recruitingConvalife (Shanghai)Jan 9, 2028180
NCT06293716Hereditary Sensory and Autonomic Neuropathies · China3Not yet recruitingConvalife (Shanghai)Dec 29, 202535
NCT06183736Stomach Neoplasms · China2Not yet recruitingConvalife (Shanghai)Jun 30, 202598
NCT02679196Lymphoma, B-Cell · United States1CompletedKarus TherapeuticsDec 24, 201823

How it is read

Names in the registry

  • “CVL237 tablets”, 3 entries
  • “KA2237”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.